Related Content
Download content relating to this event and topic.
The region’s premier knowledge-sharing platform, featuring success stories from Asian biopharmas and expert insights from global biomanufacturing leaders on the latest innovations, process optimization, and regulatory advancements.

The 13th Annual Biologics Manufacturing Asia 2026 is Asia’s premier bioprocessing-focused conference, providing a dedicated platform for regional biopharmaceutical industry stakeholders to network, explore strategic collaborations, and gain insights into the latest manufacturing technologies and advancements.
This year’s agenda is designed to highlight success stories from Asia’s leading biopharma companies while incorporating technical expertise from global biopharma leaders, top pharmaceutical companies, and regulators. Key topics will include cutting-edge manufacturing technologies such as single-use systems and end-to-end continuous processing, challenges and opportunities in biomanufacturing, advancements in upstream process development, cost optimization and timeline reduction in downstream processing, analytical characterization strategies, facility design and scale-up, emerging biologics manufacturing technologies, regulatory updates, and novel biologics modalities.
Building on the tremendous success of the 12th Annual Biologics Manufacturing Asia 2025, we are committed to delivering the most comprehensive and impactful knowledge-sharing platform at the 13th Annual Biologics Manufacturing Asia 2026.


View the Key Themes for
Biologics Manufacturing Asia 2026
Register today to secure your ticket.
Our selected experts will share insights on the latest trends, challenges, and developments in this dynamic field. Engage in unique discussions, learn about cutting-edge scientific discoveries, and explore the future of biopharmaceuticals with these influential thought leaders.


Dr. Gang Qin, Ph.D. (University of Göttingen), is the Founder and CEO of GeneQuantum Healthcare. With over 20 years of international experience in biopharmaceutical R&D and leadership—spanning roles at the Max Planck Institute and the Chinese Academy of Sciences—Dr. Qin is a recognized innovator in the field, credited with numerous high-impact scientific publications and over 180 patent applications as a core inventor.
At GeneQuantum, Dr. Qin leads the company’s mission to revolutionize targeted cancer therapies through its proprietary, enzyme-mediated site-specific conjugation technologies. Under his leadership, GeneQuantum has established a fully integrated, high-throughput platform for the discovery and manufacturing of next-generation XDC therapeutics. This end-to-end solution supports the efficient development of best-in-class and first-in-class (BIC/FIC) XDC candidates, targeting oncology and other indications with substantial unmet medical needs and high market potential.


Heonchang Lim is the Director of Formulation Development at Samsung Biologics’ CDO division, where he leads a team dedicated to developing innovative drug formulations. With over 15 years of experience in the biopharmaceutical industry, Heonchang specializes in protein drugs and vaccines.
He has successfully managed more than 50 formulation development and non-GMP DP manufacturing projects. In September 2022, he helped launch DEVELOPICK™, a platform that evaluates target molecules. Prior to joining Samsung Biologics in 2017, Heonchang served as a scientist at LG Chem, where he conducted R&D for purification and formulation development in multiple vaccine and protein drug projects.
He holds a master’s degree in medicine from Seoul National University and a bachelor’s degree in molecular biology from Catholic University.


Mr Muhammad Satrio Wicaksono is a life sciences professional with over five years of experience in vaccine formulation, fill-finish, GMP production, and facility project leadership. He has a proven track record in managing cross-functional teams, developing manufacturing strategies, and ensuring compliance with cGMP and WHO standards.
Currently, he serves as Project Leader for a USD 60M new production and QC facility, overseeing planning, technology selection, and operations strategy. He also leads quality risk management initiatives, focusing on contamination control, deviation review, and corrective/preventive actions, while liaising with external auditors to ensure alignment with global standards.
As SME Lead for Physical Barrier Systems, he develops learning journeys and trains employees to strengthen organizational knowledge. In addition, he leads new product development, managing formulation and production process optimization, technology transfer from R&D to manufacturing, and product stability strategies. He has contributed to peer-reviewed publications and international teaching programs, reflecting his commitment to advancing vaccine science and operational excellence.


Dr. Chuang received his PhD degree in Medicinal Chemistry from National Tsing Hua University. As a principal investigator in Development Center for Biotechnology (DCB), he led several drug discovery projects especially on oncology field. These topics include Top1 inhibitor, Nek2/Hec1 inhibitor, antibody-drug conjugates (ADC) and proteolysis targeting chimera (PROTAC). After more than 15 years, he left DCB and joined OBI Pharma as the director of Medicinal Chemistry and focusing on developing anti-Trop2 ADC. In 2022, Dr. Chuang co-founded HoneyBear Biosciences, and serve as the CEO.


Ikuo Tsujimoto, M.Sc., is a Research Fellow in the Process Engineering Team at Astellas Pharma Inc. and Head of Cell Manufacturing at Cellafa Bioscience Inc., a joint initiative powered by Astellas and Yaskawa Electric. He earned his master’s degree in biotechnology and has extensive experience in process development and regulatory submissions for Astellas products. He is currently leading efforts to establish robotic cell manufacturing systems named Maholo in a GMP-compliant environment at Cellafa.




Dr. Pini Tsukerman is an immunologist and co-founder of Nectin Therapeutics, a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) and immune-oncology therapies. He established Nectin’s R&D organization, built its IP portfolio, and led the company’s scientific and development strategy from inception through clinical proof-of-concept. Under his leadership, Nectin has advanced multiple ADC programs to IND-enabling stages, integrating novel payload and linker technologies, and forged strategic collaborations with leading global biopharmaceutical companies to accelerate development. Dr. Tsukerman also guided the company’s lead program, NTX1088, from concept to clinical validation, advancing Nectin’s mission to deliver transformative therapies for resistant cancers.


Charles MY Lim, a Pharmacist, with a career spanning more than 40 years, in the healthcare, life sciences and biopharmaceutical industry with expertise in bioseparations from lab to production scale, cGMP bioproduction, bioprocessing of biologics and vaccines, turnkey plasma fractionation and GMP facility design.
Started his career with MOH, Malaysia, then worked for Pharmacia Biotech, Amerham Biosciences and GE Heathcare Life Sciences (now Cytiva) as their Vice President for Asia Pacific for 27 years. During this time was also the technical expert for Pharmadule, Sweden, manufacturer of modular turnkey biopharmaceutical facilities.
Moved to Shanghai in 2007, consulted for Charles River Laboratories USA, VirusSure, Atoll GmbH, and Bio-Works UK, and served as GM & VP Asia for BIA Separations, Austria with advance technology bioprocessing of large biomolecules such a viruses and plasmids, which was recently acquired by Sartorius.
Currently based in Suzhou, Charles Lim is Director of International Business at Lisure Science (Suzhou) Co., Ltd, the leading Downstream Processing Systems and Solution Provider for the biopharmaceutical industry in China. He is also a director in Solution Biologics Malaysia – the distribution / fill finish production partner of Cansino Biologics China for their COVID-19 vaccine in Sounth East Asia.


Gary Khoo is the Head of CMC at Hummingbird Bioscience, where he oversees process and analytical development, as well as CMC operations and strategy for a portfolio of antibody-based therapies, including antibody-drug conjugates (ADCs). He holds a Ph.D. in Biochemical Engineering from the University of Birmingham, UK, and brings over 20 years of experience across drug development, CMC, and manufacturing. Dr. Khoo’s expertise encompasses a wide range of modalities—recombinant proteins, monoclonal antibodies, viral vectors and vaccines, and cell- and gene-therapy products—spanning all stages of the product lifecycle from IND enabling studies, BLA process validation to commercial manufacturing.


Dr. Qiuming (Miles) Shi is a senior biopharmaceutical executive with 15+ years of integrated experience across R&D, commercial strategy, and large-scale technical operations. He has led multiple technology transfers for mRNA vaccines, PCV13, monoclonal antibodies, and complex biologics, and has built GMP and WHO PQ–aligned quality systems in emerging markets.
Most recently, Dr. Shi served as Chief Technology Officer at PT Etana Biotechnologies in Southeast Asia, overseeing R&D, Production, Quality, Supply Chain, Digitalization and Engineering. His prior leadership roles at Merck, Sartorius, GE Healthcare, and Boehringer Ingelheim span vaccine development, bioprocessing strategy, and technical applications across Asia.
Dr. Shi combines deep scientific expertise with operational excellence and multicultural leadership, with a focus on enabling global-scale manufacturing, organizational transformation, and sustainable biopharma growth.


Jing Yi is currently at MSD International GmbH where her role involves providing regional regulatory strategies for new and existing products as well as regulatory advocacy effortsin the Asia Pacific region. Starting her career at the manufacturing facility of a multinational pharmaceutical company, she has several years of experience within the Quality function on deviation and CAPA management, audit inspection and readiness, fronting external regulatory agencies inspection and as a team lead providing Quality oversight for supplier management. Ms. Teo holds a Master of Business Administration from Arizona State University and a Bachelor of Science (Hon) from National University of Singapore.
Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.
Apply to SpeakChoose a plan that fits your role, company, and industry.
Early Bird Rate : SGD 1,495
(Valid until 2nd October 2025)
Registration Open Rate : SGD 1,695
(Valid until 4th December 2025)
Standard Rate : SGD 1,895
(Valid until 5th Feb 2026)
Final Call Rate : SGD 2,095
(Valid until 11th March 2026)
Applicable to company profiles (headquartered within the APAC region):
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
Early Bird Rate : SGD 1,995
(Valid until 2nd October 2025)
Registration Open Rate : SGD 2,195
(Valid until 4th December 2025)
Standard Rate : SGD 2,395
(Valid until 5th Feb 2026)
Final Call Rate : SGD 2,595
(Valid until 11th March 2026)
Applicable to company profiles (headquartered outside of the APAC region):
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
Early Bird Rate : SGD 4,295
(Valid until 2nd October 2025)
Registration Open Rate : SGD 4,495
(Valid until 4th December 2025)
Standard Rate : SGD 4,695
(Valid until 5th Feb 2026)
Final Call Rate : SGD 4,895
(Valid until 11th March 2026)
Applicable to company profiles:
Job Profiles: Business Development, Marketing, and Sales
Be the first in line! Register your interest now to get exclusive access to Super Early-Bird tickets - the lowest prices available - before they go live.
Contact the IMAPAC to learn about our sponsorship process, rates and more.
Visit the event page to view more content.
Download content relating to this event and topic.
Visit the event page to view more content.
Visit the awards page to view more content.
To stay informed about event updates, including date, venue, and agenda, please subscribe to our our official social media channels for real-time updates and announcements.
The conference will provide a comprehensive learning experience covering various aspects of the dynamic biopharmaceutical industry, ensuring attendees gain valuable insights and knowledge.
We are committed to ensuring the safety and well-being of all attendees. We will implement rigorous safety measures in line with local health guidelines and regulations. Specific safety measures will be communicated closer to the event date to ensure they align with the most up-to-date health recommendations. Rest assured, your safety is our priority.
We welcome presentation submissions. If you’re interested in speaking at the event, please visit this page on our website for submission guidelines and deadlines.
Our event is designed to cater to a wide range of professionals within the biopharmaceutical industry, including researchers, scientists, executives, regulatory experts, and professionals involved in drug development and manufacturing.
Participants can expect to gain insights from industry experts, network with peers, and stay up-to-date with the latest trends and innovations in biopharmaceuticals
Yes, we have networking sessions, workshops, and social events scheduled throughout the event to facilitate connections and collaborations among attendees.
Yes, we offer sponsorship and exhibition opportunities for businesses and organizations. Please visit our this page on our website for more information.
To register for the event, you'll find multiple "register" buttons on this page to get started. You’ll find detailed instructions and options for registration, including pricing and deadlines.
Don't miss out on unique networking, speaking and sponsorship opportunities.